Kezar Life Sciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Its therapies target protein homeostasis. Its lead development program, KZR-616, is a selective immunoproteasome inhibitor, which is being evaluated in severe autoimmune diseases, including lupus nephritis (LN), dermatomyositis (DM), polymyositis (PM), autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Additionally, the Company selected KZR-261 as its first clinical candidate from its protein secretion program for the treatment of cancer.